Innovative Industrial Properties (IIPR) Company presentation summary
Event summary combining transcript, slides, and related documents.
Company presentation summary
3 Aug, 2026Business overview and strategy
Diversified REIT with $2.5B invested capital, focusing on cannabis and life sciences real estate across 19 U.S. states and 111 properties.
Triple-net lease model with long-term, 15–20 year leases, minimizing recurring capital expenditures.
Strategic $270M investment in life sciences via IQHQ, enhancing sector diversification and growth opportunities.
Portfolio leased to 35+ tenants, with 90% industrial and 2% retail property mix.
Management team with deep experience in regulated industries and real estate.
Financial performance and capital structure
Q4 2025 revenue reached $66.7M, with over $1B in dividends paid since inception in 2016.
AFFO per share grew at an 8% CAGR from 2020 to Q4 2025; dividends per share grew at 11% CAGR.
Maintains a low-leverage balance sheet: 14% debt to total gross assets, $393.7M gross debt, and $105M+ liquidity.
Investment grade BBB+ rating on $291.2M unsecured senior notes due 2026.
Total return since inception exceeds 300%, outperforming major REIT and S&P 500 indices.
Portfolio composition and tenant base
Top 10 states account for 89.4% of annualized base rent, with Pennsylvania, Illinois, and Massachusetts leading.
Largest tenants include AWH, PharmaCann, Green Thumb, and Curaleaf; 66% of rent from public companies, 87% from multi-state operators.
Cannabis properties comprise 93.2% of base rent, with life sciences at 6.6%, shifting toward greater diversification.
Right of first offer on certain IQHQ asset sales and potential for warrants upon funding milestones.
Diligent underwriting and ongoing monitoring processes focus on best-in-class operators and financial health.
Latest events from Innovative Industrial Properties
- 2025 revenue, AFFO, and net income strong; IQHQ investment and leasing drive future growth.IIPR
Q4 20256 Aug 2026 - Q2 2026 saw revenue and net income growth, strong liquidity, and strategic sector investments.IIPR
Q2 20264 Aug 2026 - Diversified REIT leverages triple-net leases and life science investments for strong, sustained growth.IIPR
Investor presentation3 Aug 2026 - Tenant defaults led to lower Q1 results, but liquidity and tenant refresh efforts remain robust.IIPR
Q1 20258 Jul 2026 - Q2 revenue up 4% to $79.8M, net income $41.7M, AFFO $2.29/share, and dividend raised 4.4%.IIPR
Q2 20248 Jul 2026 - Q3 2024 revenue was $76.5M with 95.7% occupancy and strong liquidity despite industry headwinds.IIPR
Q3 20248 Jul 2026 - Q1 2026 revenue was $69M, but tenant defaults and debt maturity threaten ongoing viability.IIPR
Q1 20265 May 2026 - Diversified REIT with robust growth, strong balance sheet, and expanding life sciences exposure.IIPR
Investor presentation5 May 2026 - 2025 featured robust financials, strategic diversification, and strong governance ahead of key shareholder votes.IIPR
Proxy filing23 Apr 2026